Deputy director of FDA’s CBER departs amid mass exodus at federal health agencies
Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), joining a long list of health agency leaders who have departed since President Donald Trump began his second term in office.
Celia Witten, M.D., Ph.D., is no longer deputy director of the FDA’s Center for Biologics Evaluation and Research (CBER), joining a long list of health agency leaders who have departed since President Donald Trump began his second term in office.
